Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2010 3
2011 1
2013 1
2014 2
2015 4
2017 4
2018 1
2019 3
2020 1
2021 3
2022 2
2023 2
2024 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
Development of an integrated conceptual model of multiple sclerosis spasticity.
Cameron MH, Bethoux F, Field-Fote E, Lenderking WR, Zaiser E, Cutts KN, Wagner JM, Berwaerts J, Steinerman JR. Cameron MH, et al. Among authors: steinerman jr. Disabil Rehabil. 2024 Jun;46(13):2955-2965. doi: 10.1080/09638288.2023.2237403. Epub 2023 Jul 22. Disabil Rehabil. 2024. PMID: 37480330 Free article. Review.
CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis.
Comi G, Dadon Y, Sasson N, Steinerman JR, Knappertz V, Vollmer TL, Boyko A, Vermersch P, Ziemssen T, Montalban X, Lublin FD, Rocca MA, Volkinshtein R, Rubinchick S, Halevy N, Filippi M. Comi G, et al. Among authors: steinerman jr. Mult Scler. 2022 Apr;28(4):608-619. doi: 10.1177/13524585211032803. Epub 2021 Aug 11. Mult Scler. 2022. PMID: 34378456 Clinical Trial.
Laboratory biomarkers in Alzheimer's disease.
Steinerman JR, Honig LS. Steinerman JR, et al. Curr Neurol Neurosci Rep. 2007 Sep;7(5):381-7. doi: 10.1007/s11910-007-0059-6. Curr Neurol Neurosci Rep. 2007. PMID: 17764627 Review.
Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials.
Liu E, Schmidt ME, Margolin R, Sperling R, Koeppe R, Mason NS, Klunk WE, Mathis CA, Salloway S, Fox NC, Hill DL, Les AS, Collins P, Gregg KM, Di J, Lu Y, Tudor IC, Wyman BT, Booth K, Broome S, Yuen E, Grundman M, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Liu E, et al. Neurology. 2015 Aug 25;85(8):692-700. doi: 10.1212/WNL.0000000000001877. Epub 2015 Jul 24. Neurology. 2015. PMID: 26208959 Free PMC article. Clinical Trial.
Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial data.
Goldman MD, LaRocca NG, Rudick RA, Hudson LD, Chin PS, Francis GS, Jacobs A, Kapoor R, Matthews PM, Mowry EM, Balcer LJ, Panzara M, Phillips G, Uitdehaag BMJ, Cohen JA; Multiple Sclerosis Outcome Assessments Consortium. Goldman MD, et al. Neurology. 2019 Nov 19;93(21):e1921-e1931. doi: 10.1212/WNL.0000000000008519. Epub 2019 Oct 22. Neurology. 2019. PMID: 31641014 Free PMC article.
26 results